Targeting the EGFR and immune pathways in squamous cell carcinoma of the head and neck (SCCHN): forging a new alliance

Despite the recent approval of immune-modulatory agents, EGFR inhibition continues to be a cornerstone in the management of SCCHN namely in combination with radiotherapy in the treatment of locoregionally advanced disease as well as in platinum sensitive recurrent or metastatic disease in the first...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mol Cancer Ther
Autors principals: Saba, Nabil F, Chen, Zhuo Gerogia, Haigentz, Missak, Bossi, Paolo, Rinaldo, Alessandra, Rodrigo, Juan P, Mäkitie, Antti A., Takes, Robert P, Strojan, Primoz, Vermorken, Jan B, Ferlito, Alfio
Format: Artigo
Idioma:Inglês
Publicat: 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6830522/
https://ncbi.nlm.nih.gov/pubmed/31676542
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-19-0214
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars